Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1995-2-8
pubmed:abstractText
1. The pharmacological activities of liriodenine, isolated from Fissistigma glaucescens, were determined in isolated trachea, ileum and cardiac tissues of guinea-pigs. 2. Liriodenine was found to be a muscarinic receptor antagonist in guinea-pig trachea as revealed by its competitive antagonism of carbachol (pA2 = 6.22 +/- 0.08)-induced smooth muscle contraction. It was slightly more potent than methoctramine (pA2 = 5.92 +/- 0.05), but was less potent than atropine (pA2 = 8.93 +/- 0.07), pirenzepine (pA2 = 7.02 +/- 0.09) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, pA2 = 8.72 +/- 0.07). 3. Liriodenine was also a muscarinic antagonist in guinea-pig ileum (pA2 = 6.36 +/- 0.10) with a pA2 value that closely resembled that obtained in the trachea. 4. Liriodenine was 10 fold less potent in atrial preparations (left atria, pA2 = 5.24 +/- 0.04; right atria, pA2 = 5.35 +/- 0.09 and 5.28 +/- 0.07 for inotropic and chronotropic effects, respectively) than in smooth muscle preparations. 5. High concentration of liriodenine (300 microM) partially depressed the contractions induced by U-46619, histamine, prostaglandin F2 alpha, neurokinin A, leukotriene C4 and high K+ in the guinea-pig trachea. The inhibitions were characterized by a rightward shift in the concentration-response curves with suppression of their maximal contraction. 6. High concentration of liriodenine (300 microM) did not affect U-46619- or neurokinin A-induced tracheal contraction in the presence of nifedipine (1 microM) or in Ca(2+)-free (containing 0.2 mM EGTA) medium. 7. Neither cyclic AMP nor cyclic GMP content of guinea-pig trachealis was changed by liriodenine (30-300 microM). 8. It is concluded that liriodenine is a selective muscarinic receptor antagonist in isolated trachea, ileum and cardiac tissues of guinea-pigs. It is more potent in smooth muscle than in cardiac preparations. It also acts as a blocker of voltage-dependent Ca2+ channels at a high concentration (300 microM).
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-1000135, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-1352637, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-13651579, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-16208, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-1686739, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-1877039, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2172682, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2188581, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2447991, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2470172, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2583233, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-26747, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2704370, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2823384, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2830120, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2841607, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-2848036, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3127224, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3215279, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3272174, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3310783, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3556389, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3612532, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3754610, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3754611, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-3806594, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-39089, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-6372560, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-6987924, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-7350532, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-7902181, http://linkedlifedata.com/resource/pubmed/commentcorrection/7812621-8395388
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
113
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
275-81
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs.
pubmed:affiliation
Pharmacological Institute, College of Medicine, National Taiwan University, Taipei.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't